Strait Access Technologies

SAT is redefining the treatment of heart valve disease. As a world first, we are able to offer cost-effective and durable transcatheter aortic valve solutions for patients with rheumatic heart disease (RHD) and degenerative heart disease (DHD) in both developed and emerging economies.